Disseminated parapox (orf) in a 13‐year‐old boy with atopic dermatitis following acupuncture

recurrence of the lesions, and the treatment is ongoing. There were no abnormalities on follow-up chest X-ray, and clinical and laboratory examinations were normal. In particular, no TB-specific changes were found. Infliximab has been described in recent publications as an effective and safe treatment option for severe and treatment-refractory cases of PRP. Infliximab is generally contraindicated in cases of latent TB, because it may reactivate the disease. The ex vivo interferon-c release ELISpot assay is more sensitive than the Mantoux test for detecting TB, with a specificity of 92.5%. However, even in latent TB infection, anti-tumour necrosis factor agents may be given under preventive treatment with isoniazid or rifampicin and regular monitoring. As this case demonstrates, even in patients with high risk of reactivation of latent TB infection, immunosuppressive treatment with infliximab may be an option for PRP under isoniazid prophylaxis.